Illumina Posts 1 Percent Decline in Q3 Revenues, Plans Restructuring | GenomeWeb

This article has been updated to include additional information from Illumina's conference call.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today reported that its third-quarter revenues fell 1 percent year over year, in line with the preliminary figure it offered earlier in the month, and it will undertake a restructuring.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.